Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-02-13 am EST			5-day change	1st Jan Change
310.60 ^DKK	+1.32%		+5.11%	-4.50%

Feb. 13	Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows	RE
Feb. 13	Novo Nordisk's Wegovy Tablet Reaches 38,000 New Prescriptions in the US	FW

NOVO NORDISK : Gets a Buy rating from Berenberg

Published on 01/12/2026 at 04:40 am EST

MarketScreener with dpa-AFX Analyser

NOVO NORDISK A/S

+1.32%

Berenberg is positive on the stock with a Buy rating. The target price is unchanged and still at DKK 400.

Latest news about Novo Nordisk A/S

Feb. 13	Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows	RE
Feb. 13	Novo Nordisk's Wegovy Tablet Reaches 38,000 New Prescriptions in the US	FW
Feb. 13	Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows	RE
Feb. 13	Novo's Wegovy pill tracks over 38,000 prescriptions in fifth week	RE
Feb. 13	Biocon aims for revenue surge with rollout of generic weight-loss drugs	RE
Feb. 13	US prescriptions for Novo's Wegovy pill were 38,220 (not '38,909') for week ended Feb 6 - IQVIA data shared by analyst shows	RE
Feb. 13	NOVO NORDISK : Barclays reiterates its Neutral rating	ZD
Feb. 13	PriorNilsson Yield Down 0.79 Percent in January – Tougher Start to 2026	FW
Feb. 13	US could take action including fines against Hims after brief Wegovy copy launch	RE
Feb. 13	PriorNilsson Sverige Aktiv Up 3.26 Percent in January – Optimistic Start	FW
Feb. 13	Barclays Lowers Price Target for Novo Nordisk to 340 Danish Kroner (from 360), Reiterates Equal Weight - BN	FW
Feb. 13	Novo Nordisk Estimates Updated as Berenberg Notes 'Cautious' FY26 Guidance; Price Target Down	MT
Feb. 13	AlphaValue/Baader Europe Cuts Novo Nordisk Price Target, Forecasts Amid Outlook Downgrades, Competitive Pressures	MT
Feb. 12	Sector Update: Health Care Stocks Rise Late Afternoon	MT
Feb. 12	Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision	RE

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

69,150

Sector

Pharmaceuticals

Calendar

Mar. 26 - Annual General Meeting

More about the company